Pituitary-directed medical treatment of Cushing’s disease

References

• Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab.88(12), 5593–5602 (2003).
   PubMed Web of Science ®Google Scholar
• Biller BMK, Grossman AB, Stewart PM et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab.93, 2454–2462 (2008).
   PubMed Web of Science ®Google Scholar
• Bourdeau I, Bard C, Forget H, Boulanger Y, Cohen H, Lacroix A. Cognitive function and cerebral assessment in patients who have Cushing’s syndrome. Endocrinol. Metab. Clin. North Am.34(2), 357–369 (2005).
   PubMed Web of Science ®Google Scholar
• Mancini T, Doga M, Mazziotti G, Giustina A. Cushing’s syndrome and bone. Pituitary7(4), 249–252 (2004).
   PubMedGoogle Scholar
• Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao AM. Cushing’s syndrome. Endocrinol. Metab. Clin. North Am.37, 135–149 (2008).
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing’s syndrome. Pituitary7(4), 253–256 (2004).
   PubMedGoogle Scholar
• Pivonello R, Faggiano A, Lombardi G et al. The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol. Metab. Clin. North Am.34, 327–339 (2005).
   PubMed Web of Science ®Google Scholar
• Faggiano A, Pivonello R, Spiezia S et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab.88, 2527–2533 (2003).
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Spiezia S et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J. Clin. Endocrinol. Metab.84, 2664–2672 (1999).
   PubMed Web of Science ®Google Scholar
• Patil CG, Prevedello DM, Lad SP et al. Late recurrences of Cushing’s disease after initial successful transsphenoidalsurgery. J. Clin. Endocrinol. Metab.93, 358–362 (2008).
   PubMed Web of Science ®Google Scholar
• Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. J. Clin. Endocrinol. Metab.80(11), 3114–3120 (1995).
   PubMed Web of Science ®Google Scholar
• Hammer GD, Tyrrell JB, Lamborn KR et al. Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J. Clin. Endocrinol. Metab.89(12), 6348–6357 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann BM, Fahlbusch R. Treatment of Cushing’s disease: a retrospective clinical study of the latest 100 cases. Front. Horm. Res.34, 158–184 (2006).
   PubMed Web of Science ®Google Scholar
• Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin. Endocrinol. (Oxf.)63(5), 549–559 (2005).
   PubMed Web of Science ®Google Scholar
• Mullan KR, Atkinson B. Endocrine clinical update: where are we in the therapeutic management of pituitary-dependent hypercortisolism? Clin. Endocrinol.68, 327–337 (2008).
   PubMed Web of Science ®Google Scholar
• Castinetti F, Nagai M, Dufour H et al. gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur. J. Endocrinol.156(1), 91–98 (2007).
   PubMed Web of Science ®Google Scholar
• Gumbs AA, Gagner M. Laparoscopic adrenalectomy. Best Pract. Res. Clin. Endocrinol. Metab.20(3), 483–499 (2006).
   PubMed Web of Science ®Google Scholar
• Assie G, Bahurel H, Coste J et al. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. J. Clin. Endocrinol. Metab.92(1), 172–179 (2007).
   PubMed Web of Science ®Google Scholar
• Blevins LS Jr, Christy JH, Khajavi M, Tindall GT. Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab.83, 63–67 (1998).
   PubMed Web of Science ®Google Scholar
• Miller JW, Crapo L. The medical treatment of Cushing’s syndrome. Endocr. Rev.14(4), 443–458 (1993).
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol. Metab. Clin. North Am.28, 211–222 (1999).
   PubMed Web of Science ®Google Scholar
• Nieman LK. Medical therapy of Cushing’s Disease. Pituitary5(2), 77–82 (2002).
   PubMedGoogle Scholar
• Morris D, Grossman A. The medical management of Cushing’s syndrome. Ann. NY Acad. Sci.970, 119–133 (2002).
   PubMed Web of Science ®Google Scholar
• Arnaldi G, Cardinaletti M, Boscaro M Advances in medical treatment of Cushing’s disease. Expert Rev. Endocrinol Metab.2(6), 735–743 (2007).
   PubMedGoogle Scholar
• Alexandraki KI, Grossman AB. Pituitary-targeted medical therapy of Cushing’s disease. Expert Opin. Investig. Drugs17(5), 669–677 (2008).
   PubMed Web of Science ®Google Scholar
• Krieger DT, Amorosa L, Linick F. Cyproheptadine-induced remission of Cushing’s disease. N. Engl. J. Med.293(18), 893–896 (1975).
   PubMed Web of Science ®Google Scholar
• Sonino N, Fava GA, Fallo F, Franceschetto A, Belluardo P, Boscaro M. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing’s disease. Pituitary3(2), 55–59 (2000).
   PubMedGoogle Scholar
• Kristiansen K, Dahl SG. Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT2C receptor interactions. Eur. J. Pharmacol.306(1–3), 195–210 (1996).
   PubMed Web of Science ®Google Scholar
• Tepavcevic D, Giljevic Z, Aganovic I et al. Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans. J. Endocrinol. Invest.18(6), 427–430 (1995).
   PubMed Web of Science ®Google Scholar
• Seibyl JP, Krystal JH, Price LH et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects Psychiatry Res.38(3), 227–236 (1991).
   PubMed Web of Science ®Google Scholar
• Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med.8(11), 1281–1287 (2002).
   PubMed Web of Science ®Google Scholar
• Heaney AP. Novel medical approaches for the treatment of Cushing’s disease. J. Endocrinol. Invest.27(6), 591–595 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrosi B, Dall’Asta C, Cannavo S et al. Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing’s disease. Eur. J. Endocrinol.151(2), 173–178 (2004).
   PubMed Web of Science ®Google Scholar
• Giraldi FP, Scaroni C, Arvat E et al. Effect of protracted treatment with rosiglitazone, a PPAR-γ agonist, in patients with Cushing’s disease. Clin. Endocrinol.64(2), 219–224 (2006).
   PubMed Web of Science ®Google Scholar
• Cannavo S, Arosio M, Almoto B, Dall’Asta C, Ambrosi B. Effectiveness of long-term rosiglitazone administration in patients with Cushing’s disease. Clin. Endocrinol. (Oxf.)63(1), 118–119 (2005).
   PubMed Web of Science ®Google Scholar
• Cannavo S, Ambrosi B, Chiodini I et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-γ ligand, rosiglitazone, in Cushing’s disease. J. Endocrinol. Invest.27(5), RC8–RC11 (2005).
   Web of Science ®Google Scholar
• Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing’s disease. J. Clin. Endocrinol. Metab.90(3), 1340–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Morcos M, Fohr B, Tafel J et al. Long-term treatment of central Cushing’s syndrome with rosiglitazone. Exp. Clin. Endocrinol. Diabetes115, 292– 297 (2007).
   PubMed Web of Science ®Google Scholar
• Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB. The PPAR-γ activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson’s syndrome. Clin. Endocrinol. (Oxf.)64(5), 519–522 (2006).
   PubMed Web of Science ®Google Scholar
• Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness of rosiglitazone therapy in Nelson’s syndrome. J. Clin. Endocrinol. Metab.92(5), 1758–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Catrina SB, Virtanen K, Hällsten K, Lönnqvist F, Nuutila P, Brismar K. Effect of rosiglitazone on early-morning plasma cortisol levels. Neuro Endocrinol. Lett.26(6), 763–776 (2005).
   PubMed Web of Science ®Google Scholar
• Barbaro D, Lapi P, Orsini P, Pasquini C, Ciaccio S. Pioglitazone treatment in Cushing’s disease. J. Endocrinol. Invest.28(4), 388–389 (2005).
   PubMed Web of Science ®Google Scholar
• Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol. Rev.78(1), 189–225 (1998).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ. Novel insights in dopamine receptor physiology. Eur. J. Endocrinol.156(Suppl. 1), S13–S21 (2007); erratum in: Eur. J. Endocrinol.157(4), 543 (2007).
   Google Scholar
• Pivonello R, Ferone D, de Herder WW. Dopamine receptor expression and function in corticotroph pituitary tumors. J. Clin. Endocrinol. Metab.89(5), 2452–2462 (2004).
   PubMed Web of Science ®Google Scholar
• de Bruin C, Pereira AM, Feelders RA et al. Co-expression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J. Clin. Endocrinol. Metab.9(4), 118–1124 (2009).
   Google Scholar
• Chen CL, Dionne FT, Roberts JL.Regulation of the pro-opiomelanocortin mRNA levels in rat pituitary by dopaminergic compounds. Proc. Natl Acad. Sci. USA80(8), 2211–2215 (1983).
   PubMed Web of Science ®Google Scholar
• Loeffler JP, Demeneix BA, Kley NA, Höllt V. Dopamine inhibition of proopiomelanocortin gene expression in the intermediate lobe of the pituitary. Interactions with corticotropin-releasing factor and the β-adrenergic receptors and the adenylate cyclase system. Neuroendocrinology47(2), 95–101 (1988).
   PubMed Web of Science ®Google Scholar
• Pardy K, Carter D, Murphy D. Dopaminergic mediation of physiological changes in proopiomelanocortin messenger ribonucleic acid expression in the neurointermediate lobe of the rat pituitary. Endocrinology126(6), 2960–2964 (1990).
   PubMed Web of Science ®Google Scholar
• Saiardi A, Borrelli E. Absence of dopaminergic control on melanotrophs leads to Cushing’s-like syndrome in mice. Mol. Endocrinol.12(8), 1133–1139 (1998).
   PubMedGoogle Scholar
• Laurent V, Kimble A, Peng B, Zhu P, Pintar JE, Steiner DF, Lindberg I. Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion. Proc. Natl Acad. Sci. USA99(5), 3087–3092 (2002).
   PubMed Web of Science ®Google Scholar
• Shomali ME, Hussain MA. Cushing’s syndrome: from patients to proteins. Eur. J. Endocrinol.143(3), 313–315 (2000).
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Waaijers AM et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J. Mol. Endocrinol.42(1), 47–56 (2009).
   PubMed Web of Science ®Google Scholar
• de Bruin C, Feelders RA, Lamberts SW, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s syndrome. Rev. Endocr. Metab. Disord. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Miyoshi T, Otsuka F, Takeda M et al. Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J. Endocrinol. Invest.27(11), 1055–1059 (2004).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J. Endocrinol. Invest.22(11), 860–865 (1999).
   PubMed Web of Science ®Google Scholar
• Casulari LA, Naves LA, Mello PA, Pereira Neto A, Papadia C. Nelson’s syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm. Res.62(6), 300–305 (2004).
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, Cappabianca P et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J. Clin. Endocrinol. Metab.94(1), 223–230 (2008).
   PubMed Web of Science ®Google Scholar
• Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Long-term therapy with cabergoline in Cushings disease. Presented at: ENDO 08; The Endocrine Society’s 50th Annual Meeting. San Francisco, CA, USA, 5–18 June 2008.
   Google Scholar
• Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V, Rodien P. Use of cabergoline in persisting Cushing’s disease. Ann. Endocrinol.67(4), 353–356 (2006).
   PubMed Web of Science ®Google Scholar
• T’Sjoen G, Defeyter I, Van De Saffele J, Rubens R, Vandeweghe M. Macroprolactinemia associated with Cushing’s disease, successfully treated with cabergoline. J. Endocrinol. Invest.25(2), 172–175 (2002).
   PubMed Web of Science ®Google Scholar
• Castillo VA, Gomez NV, Lalia JC, Cabrera Blatter MF, Garcia JD. Cushing’s disease in dogs: cabergoline treatment. Res. Vet. Sci.85, 26–34 (2008).
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med.356(1), 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and risk of cardiac-valve regurgitation. N. Engl. J. Med.356(1), 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Roth BL. Drugs and valvular heart disease. N. Engl. J. Med.356(1), 6–9 (2007).
   PubMed Web of Science ®Google Scholar
• Rasmussen VG, Poulsen SH, Dupont E, østergaard K, Safikhany G, Egeblad H. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson’s disease. J. Intern. Med.263(1), 90–98 (2008).
   PubMed Web of Science ®Google Scholar
• Kars M, Delgado V, Holman ER et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab.93(9), 3348–3356 (2008).
   PubMed Web of Science ®Google Scholar
• Kars M, Pereira AM, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol.159(4), 363–367 (2008).
   PubMed Web of Science ®Google Scholar
• Colao A, Galderisi M, Di Sarno A et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab.93(10), 3777–3784 (2008).
   PubMed Web of Science ®Google Scholar
• Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. (Oxf.)70(1), 104–108 (2009).
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front. Neuroendocrinol.20(3), 157–198 (1999).
   PubMed Web of Science ®Google Scholar
• Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab.93(8), 2957–2968 (2008).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol.9(1), 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• Van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing’s disease. Pituitary7(4), 257–264 (2004).
   PubMedGoogle Scholar
• Arnaldi G, Polenta B, Cardinaletti M, Boscaro M. Potential indications for somatostatin analogs in Cushing’s syndrome. J. Endocrinol. Invest.28(11 Suppl. Int.), 106–110 (2005).
   PubMed Web of Science ®Google Scholar
• Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting somatostatin analogue SMS 201–995 on ACTH secretion in Nelson’s syndrome and Cushing’s disease. Acta Endocrinol. (Copenh.)6, 760–766 (1989).
   Google Scholar
• Stalla GK, Brockmeier SJ, Renner U et al. Octreotide exerts different effects in vivo and in vitroin Cushing’s disease. Eur. J. Endocrinol.2, 125–131 (1994).
   Google Scholar
• Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic–pituitary–adrenal function in patients with corticotropin hypersecretion. J. Endocrinol. Invest.3, 257–261 (1990).
   Google Scholar
• Van der Hoek J, Lamberts SWJ, Hofland LJ. Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur. J. Endocrinol.156, S45–S51 (2007).
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, Feelders R et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol.152(4), 645–654 (2005).
   PubMed Web of Science ®Google Scholar
• Batista DL , Zhang X, Gejman R et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab.91(11), 4482–4488 (2006).
   PubMed Web of Science ®Google Scholar
• Invitti C, de Martin M, Brunani A, Piolini M, Cavagnini F. Treatment of Cushing’s syndrome with the long-acting somatostatin analogue SM 201-995 (sandostatin). Clin. Endocrinol. (Oxf.)32(3), 275–281 (1990).
   PubMed Web of Science ®Google Scholar
• Stafford PJ, Kopelman PG, Davidson K et al. The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects. Clin. Endocrinol. (Oxf.)30(6), 661–666 (1989).
   PubMed Web of Science ®Google Scholar
• Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S, Pfeiffer EF. Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin. Wochenschr.4, 173–175 (1976).
   Google Scholar
• Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology4, 1147–1154 (1982).
   Google Scholar
• Kraus J, Woltje M, Hollt V. Regulation of mouse somatostatin receptor type 2 gene expression by glucocorticoids. FEBS Lett.2, 200–204 (1999).
   Google Scholar
• Kraus J, Woltje M, Schonwetter N, Hollt V. Alternative promoter usage and tissue specific expression of the mouse somatostatin receptor 2 gene. FEBS Lett.3, 165–170 (1998).
   Google Scholar
• Van der Hoek J, Waaijers M, van Koetsveld PM et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab.289(2), E278–E287 (2005).
   PubMed Web of Science ®Google Scholar
• Strowski MZ, Dashkevicz MP, Parmar RM et al. Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology6, 339–346 (2002).
   Google Scholar
• Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br. J. Pharmacol.1, 109–121 (2003).
   Google Scholar
• Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J. Clin. Endocrinol. Metab.86, 2976–2981 (2001).
   PubMed Web of Science ®Google Scholar
• Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur. J. Endocrinol.153(3), R7–R10 (2005).
   Web of Science ®Google Scholar
• Boscaro M, Ludlam WH, Atkinson B et al. Treatment of pituitary-dependent Cushing’s disease with multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, Phase II trial. J. Clin. Endocrinol. Metab.94(1), 115–122 (2009).
   PubMed Web of Science ®Google Scholar
• Unger N, Serdiuk I, Sheu SY et al. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clin. Endocrinol. (Oxf.)68, 850–857 (2008).
   PubMed Web of Science ®Google Scholar
• Paez-Pereda M, Kovalovsky D, Hopfner U et al. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest.108(8), 1123–1131 (2001).
   PubMed Web of Science ®Google Scholar
• Lauber M, Theodoropoulou M, Sievers C. New aspects in the diagnosis and treatment of Cushing disease. Front. Horm. Res.35, 169–178 (2006).
   PubMed Web of Science ®Google Scholar
• Castillo V, Giacomini D, Paez-Pereda M et al. Retinoic acid as a novel medical therapy for Cushing’s disease in dogs. Endocrinology147(9), 4438–4444 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein ZP, Chanan-Khan A, Miller KC, Northfelt DW, Lopez-Berestein G, Gill PS. A multicenter Phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi’s sarcoma. Cancer95(12), 2555–2561 (2002).
   PubMed Web of Science ®Google Scholar
• Aboulafia DM, Norris D, Henry D et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a Phase 2 multicenter clinical trial. Arch. Dermatol.139(2), 178–186 (2003).
   PubMed Web of Science ®Google Scholar
• Miles SA, Dezube BJ, Lee JY et al.; AIDS Malignancy Consortium. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi’s sarcoma. AIDS16(3), 421–429 (2002).
   PubMed Web of Science ®Google Scholar
• Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science288(5463), 154–157 (2000).
   PubMed Web of Science ®Google Scholar
• Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal.19(11), 2304–2316 (2007).
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N. Engl. J. Med.352(23), 2457–2458 (2005).
   PubMed Web of Science ®Google Scholar
• Vignati F, Loli P. Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. J. Clin. Endocrinol. Metab.81(8), 2885–2890 (1996).
   PubMed Web of Science ®Google Scholar